ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40243565

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.

Mejía-Guzmán JE and 4 others. Int J Mol Sci, 2025. Cited by 60 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. Papers, record 40243565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40243565

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
60
iCite
Relative citation ratio, by iCite
18.42, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mejía-Guzmán JEJeysson E
2Belmont-Hernández RARamón A
3Chávez-Tapia NCNorberto Chttps://orcid.org/0000-0002-7451-3306
4Uribe MMisaelhttps://orcid.org/0000-0002-6514-7869
5Nuño-Lámbarri NNatalia

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Non-alcoholic Fatty Liver DiseaseMajor topic
Humans
Animals
Oxidative Stress
Lipid Metabolism
Gastrointestinal Microbiome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References181

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,964,438Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA.Elife2021https://conductscience.org/library/papers/34964438PubMed
237,437,769HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation.Exp Cell Res2023https://conductscience.org/library/papers/37437769PubMed
339,505,261Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells.J Lipid Res2024https://conductscience.org/library/papers/39505261PubMed
437,732,990A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.Hepatology2024https://conductscience.org/library/papers/37732990PubMed
538,851,997EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol2024https://conductscience.org/library/papers/38851997PubMed
638,415,019Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.JHEP Rep2024https://conductscience.org/library/papers/38415019PubMed
738,293,761Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.Liver Int2024https://conductscience.org/library/papers/38293761PubMed
837,886,435Intestinal Pgc1α ablation protects from liver steatosis and fibrosis.JHEP Rep2023https://conductscience.org/library/papers/37886435PubMed
938,003,543Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.Int J Mol Sci2023https://conductscience.org/library/papers/38003543PubMed
1039,155,764Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).J Med Econ2024https://conductscience.org/library/papers/39155764PubMed

1 to 10 of 181

See all 181 references

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.

PMIDTitleJournalYearIn PapersSource
42,947,715Prevalence and steatosis severity of MASLD in patients with type 2 diabetes mellitus in Kuwait.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42947715PubMed
42,943,326The MASLD-Heart Axis: Biological Mechanisms, Cardiac Remodeling, and Clinical Implications.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943326PubMed
42,939,842Xiaochaihutang Extract Ameliorates Metabolic Dysfunction-Associated Steatohepatitis in Mice and Modulates the Gut-Liver Axis.Antioxidants (Basel)2026https://conductscience.org/library/papers/42939842PubMed
42,871,997
Hepatic Overexpression of a Novel Soluble Endogenous Transforming Growth Factor β Type II Receptor-Immunoglobulin G1 Fc Fusion Protein (TβRII-SE/Fc) Attenuates Early Stage Metabolic Dysfunction-Associated Steatotic Liver Disease in Rats.
ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42871997PubMed
42,865,473GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.Front Med (Lausanne)2026https://conductscience.org/library/papers/42865473PubMed
42,794,785AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation.Int J Mol Sci2026https://conductscience.org/library/papers/42794785PubMed
42,792,248Betaine in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms of Action and Therapeutic Potential.Antioxidants (Basel)2026https://conductscience.org/library/papers/42792248PubMed
42,737,521Housing at 27 °C, a Near-Thermoneutral Temperature, Exacerbates Metabolic Dysfunction-Associated Steatohepatitis in C57BL/6J Mice.Int J Mol Sci2026https://conductscience.org/library/papers/42737521PubMed
42,703,413A Shared EGR1-IL-32-Macrophage Polarisation Signature in Rheumatoid Arthritis and Metabolic Dysfunction-Associated Steatotic Liver Disease.J Inflamm Res2026https://conductscience.org/library/papers/42703413PubMed
42,690,471From metabolites to membrane vesicles: Unifying gut microbial signals in obesity, t2dm, and MASLD.World J Microbiol Biotechnol2026https://conductscience.org/library/papers/42690471PubMed

1 to 10 of 58

See all 58 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
THRB7,068PubTator's text mininghttps://conductscience.org/library/genes/7068

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40243565

GET https://conductscience.org/api/papers/v1/40243565/references?page=2

API referenceFor AI assistants